Skip to main content
. 2015 Nov 3;56(12):1921–1930. doi: 10.1111/epi.13224

Table 3.

Incidence of any TEAEs and TEAEs related to lacosamide

N = 571 patients Any TEAEa n (%) Lacosamide‐related TEAE n (%)
Any 277 (48.5) 164 (28.7)
Fatigue 71 (12.4) 59 (10.3)
Dizziness 63 (11.0) 50 (8.8)
Convulsion 29 (5.1) 10 (1.8)
Headache 24 (4.2) 15 (2.6)
Nausea 21 (3.7) 17 (3.0)
Depression 17 (3.0) 7 (1.2)
Tremor 15 (2.6) 9 (1.6)
Gait disturbance 14 (2.5) 11 (1.9)
Somnolence 12 (2.1) 11 (1.9)

TEAE, treatment‐emergent adverse event.

a

In ≥2% of patients.